← Research library

Thymopentin, G-CSF and chemotherapy-associated fever

Randomized study in people · 1994

What was studied
100 patients receiving highly myelosuppressive chemotherapy for advanced carcinoma randomized across four arms.
Main finding
Chemotherapy-related febrile episodes · 52% with thymopentin versus 64% with placebo. The difference was not statistically significant.

Reported findings and study design

Reported findings

Prospective randomized comparison of thymopentin, subcutaneous G-CSF, both agents, and placebo. Cochrane’s extraction lists thymopentin 50 mg IM every other day starting two days after chemotherapy and continuing until the next cycle.

Population or model 100 patients receiving highly myelosuppressive chemotherapy for advanced carcinoma randomized across four arms.

Dose, route and schedule

Prospective randomized comparison of thymopentin, subcutaneous G-CSF, both agents, and placebo. Cochrane’s extraction lists thymopentin 50 mg IM every other day starting two days after chemotherapy and continuing until the next cycle.

Protocol source ↗ · Original indexed abstract for findings. The dosing detail comes from the Cochrane study description.

Results · Original indexed abstract for findings. The dosing detail comes from the Cochrane study description.
MeasureResultComparison, timing and statistics
Chemotherapy-related febrile episodes52% with thymopentin versus 64% with placebo. The difference was not statistically significant.
G-CSF and combination22% with G-CSF versus 64% with placebo (p<0.001). Adding thymopentin did not significantly improve the result with G-CSF alone.

The accessible journal abstract does not supply per-arm denominators or a combination-arm percentage. The study measured supportive-care outcomes during chemotherapy.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The accessible journal abstract does not supply per-arm denominators or a combination-arm percentage. The study measured supportive-care outcomes during chemotherapy.

Source details

Original indexed abstract

Original indexed abstract for findings. The dosing detail comes from the Cochrane study description.

Sources checked

Added to the library

Citation

Randomized trialEnglish abstract

V. Gebbia, R. Valenza, A. Testa, G. Cannata, N. Borsellino, N. Gebbia. Thymopentin, G-CSF and chemotherapy-associated fever Anticancer Research 14(2B), 731–734.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards